Top Markets
Coin of the day
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
Rang in aandelen #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Aandeelprijs
$1.81
Laatst gesynchroniseerd: 2026-08-21
Marktkapitalisatie
$77.00M
Verandering (1 dag)
1.30%
Verandering (1 jaar)
-23.63%
Land
US
Handel Annovis Bio, Inc. (ANVS)

Categorie

Dividendrendementgeschiedenis voor Annovis Bio, Inc. (ANVS)
Het dividendrendement (TTM) van Annovis Bio, Inc. (aandelsymbool: ANVS) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Annovis Bio, Inc. (ANVS) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH